We are committed to finding effective treatment for life-threatening infectious diseases.
A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology
Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
The Indirect Cause of Mortality in Covid-19 The journal ‘Phage’ recently published a review suggesting the use of bacteriophages in patients with severe Covid-19. According to the review, the indirect cause of mortality in patients with Covid-19 is due to miscommunication between the innate and......
Mutations in the Pandemic Influenza Virus Since seasonal influenza virus is constantly mutating through antigenic shift, it is necessary to develop new vaccines every year, but it could take over 6 months to develop a new vaccine that matches the new virus. In a pandemic......
Development of Robot Bacteriophages with CRISPER-Cas9 Technology iNtRON’s PHAGERUS® Technology iNtRON’s PHAGERUS® technology discovered the applicability of bacteriophage as a virus neutralizing vaccine, and has secured a number of related core technologies from late 2018. Based on this, we are actively investing in PHAGERUS® by launching......
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
